Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
- EligibilityCriteria: Inclusion Criteria:  Adults > 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy Treatment naive adult acute myeloid leukemia patients  Exclusion Criteria:  Acute myeloid leukemia patients receiving azacitidine and venetoclax as salvage therapy will be excluded Patients who are pregnant or breast-feeding - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy. - SamplingMethod: Non-Probability Sample